Cartesian Therapeutics (RNAC) Goodwill (2023 - 2026)

Cartesian Therapeutics (RNAC) has reported Goodwill for 4 consecutive years, with $48.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill changed 0.0% year-over-year to $48.2 million; the TTM figure through Mar 2026 stood at $48.2 million (changed 0.0% YoY), while the FY2025 annual figure was $48.2 million, changed 0.0% from the prior year.
• Goodwill steadied at $48.2 million in Q1 2026 per RNAC's latest filing, from $48.2 million in the prior quarter.
• Across five years, Goodwill topped out at $48.2 million in Q4 2023 and bottomed at $48.2 million in Q4 2023.
• Historically, Goodwill has averaged $48.2 million across 4 years, with a median of $48.2 million in 2023.
• On a YoY basis, Goodwill climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
• Cartesian Therapeutics' Goodwill stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025, then changed by 0.0% to $48.2 million in 2026.
• Business Quant data shows RNAC's Goodwill at $48.2 million in Q1 2026, $48.2 million in Q4 2025, and $48.2 million in Q3 2025.